Top Company News:
From Baseball to Bioelectronics: Pro Pitcher Turned CEO Scientist Explains Deep Brain Stimulation Tech
June 15, 2017 by Laura Panjwani of R&D Magazine
"Right now there has been almost 135,000 patients implanted with a [deep brain stimulation] device, but not ours. It is a very safe, well-tolerated procedure. Patients regain almost the level of function they had before their disease. The challenge now is— how do we make the procedure easier for the neurologist to maintain the patient in the therapeutic window? The question really is not will it work, the question it is how do we make it better so we can get more patients implanted."
May 30, 2017 by Javier Hasse of BenZingA
...Rosellini explained how Nexeon was going to enter the public markets through an alternative mechanism that does not involve the same steps as most IPOs in the U.S.
Following the steps of companies like Intel Corporation INTC 0.22%, which raised only $5 million when it went public, Nexeon will try to be “really capital-conscious and prove out the business at each stage,” the CEO said. “That way, we will be able to look at our investors and tell them we thought about them, as opposed to raising a ton of VC [venture capital] money at crazy valuations, not wanting to go public, continuing to try to drive and grow and get market share, but never getting to profitability.”
Nexeon CEO on the Brain Chip Targeting Parkinson's, Lou Gehrig's Disease, and Other "Cyborg" Technologies
May 29, 2017 by Javier Hasse of BenZingA
Nexeon is currently producing a deep brain stimulation device, expected to launch in Europe in the first quarter of 2018. The company’s first commercial product basically consists of an implant, similar to a pacemaker, which connects via Bluetooth to an Apple Inc. (AAPL 0.34%) iPad clinical programmer. This allows users to turn the device on and off, steer the current to the places that need it, and even record local field potentials, “which tell them what the brain is doing, and when it is being stimulated or it’s going into a tremor state,” Rosellini explained.
Nexeon’s product will initially target Parkinson’s disease-affected brains. However, the company is also conducting preclinical studies in dysphasia from ALS, "Lou Gehrig’s disease," and recently completed a mouse study for overactive bladder and asthma, with positive results.
“We expect to move into other markets with the device once we launch a successful DBS product,” Rosellini added.
Mar 30, 2017 - by Niahm Marriot of Drug Target Review
Nexeon MedSystems has licensed a portfolio of patents from Marathon Patent Group. The portfolio of 86 patents originated from Siemens AG, one of the world’s preeminent engineering companies. This portfolio protects innovations in the Internet-of-Things (IoT) space, which can be described as the interconnection via the internet of computing devices embedded in everyday objects, enabling them to send and receive data. This technology can be utilised in a wide variety of medical device applications, most notably in hospitals, nursing facilities, or patients’ homes.